Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
about
Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen studyHematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective.Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.Compliance with therapeutic guidelines in Radiation Therapy Oncology Group prospective gastrointestinal clinical trials.Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11)Potential risk of mitomycin C at high concentrations on peripheral nerve structure.US intergroup anal carcinoma trial: tumor diameter predicts for colostomy.Chemoradiotherapy with a radiation boost for anal cancer decreases the risk for salvage abdominoperineal resection: analysis from the national cancer data base.Variation in the Use of Chemoradiotherapy for Stage II and III Anal Cancer: Analysis of the National Cancer Data Base.Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma.Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patientsDosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.Pancytopenia and Severe Gastrointestinal Toxicities Associated with 5-Fluorouracil in a Patient with Thymidylate Synthase (TYMS) PolymorphismImpaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors.Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional dataSafety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis.Anal adenocarcinoma requires prophylactic inguinal nodal treatment: Results from a single Chinese institutionImpact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature.Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncologyOctreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinomaTechnical aspects of radiation therapy for anal cancer.Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapyChemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature.Cisplatin in cancer therapy: molecular mechanisms of actionMultimodality therapy in penile cancer: when and which treatments?Anal squamous cell carcinoma: an evolution in disease and management.IMRT, RapidArc® and conformal radiotherapy in the treatment of tumours of the anal canal.Anal cancer treatment: current status and future perspectives.RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canalInterstitial high-dose rate brachytherapy as boost for anal canal cancer.Improving chemoradiotherapy with nanoparticle therapeutics.Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapyExpanding epigenomics to archived FFPE tissues: an evaluation of DNA repair methodologies
P2860
Q28390359-E404FD4E-6214-41B1-BBB2-41F98FA66D21Q30235359-3E145D85-9084-4D84-9229-E296733466A4Q30409533-903C4274-D3D3-4697-A593-E57CAA34B8DCQ30411811-8EA3B568-E318-4BEB-9F8B-AAD80AD43D41Q30415832-C77F4BCB-A7F3-4112-BACB-0730750504D9Q30416301-E75BADA3-E109-4F91-8D29-C56590C272B7Q30431142-5CC417A8-3381-4FDC-9584-CF6B7BC568CEQ30436928-C6AF3E12-6C16-4A4E-A2A9-7FCF19F0B336Q30832021-08C4A38F-F9B9-4FE8-A4EF-A5B986FA8AB5Q31116556-F4D7263E-CF2B-460F-984B-8F39A3E0747AQ33162775-2B1817A5-B17B-4E97-B851-4ACB5DE01FC7Q33422634-F6BA7DBF-DF85-4BB8-B92D-69E3C8508AB0Q33429717-97FBFB27-82D2-423B-949F-F73BA9F924D4Q33431168-249A6A22-664C-4384-81E1-2CDECA349B39Q33436235-331FB657-35B7-425D-9B04-661863B81E6BQ33457264-6BD18665-19C9-4583-B31C-B47F81374F8DQ33578833-9C1107C5-06BC-4BAF-BAA8-F35381FD58A8Q33608156-9C5867F2-2707-427B-9EF9-302BE50E4B2AQ33646367-EE94F7AB-AD95-48AB-B9BE-5298986DA12BQ33702377-E077C0EF-8CF9-4F85-A64D-B21C8A66423EQ33721749-21AAD047-2B5C-466D-9A95-C4EB8D2B2591Q33729819-D22B2679-BBE6-468A-849C-445D86A46494Q33759776-AFB52D51-BE65-4E5B-B8CA-A0EE809AF284Q33783068-F18EEBA3-8DF4-4846-89F9-955D9556F052Q33797364-D8A0BD91-FD50-4965-B010-FCDD835C718AQ33803090-B6D8F021-65AE-4754-B29A-E052F94B768DQ33811309-A1599B6F-31E2-4444-93A9-48F9A1B2110AQ33820797-60D1C071-3FF2-447E-97AD-5C55786A0617Q33885578-DA046631-2754-4EC1-8146-D35CA0DD7FEDQ33888085-518677CC-9AF0-4846-8AAA-93947E0E1845Q34098163-9A0F49E2-17C4-4274-BBB3-FDA052DF5EFDQ34182566-F56D6125-1225-466A-BF60-69445FF8AC3DQ34255528-07AAF876-1569-4F2D-BED5-726D47A651DAQ34372829-1EA5C446-39C3-4137-A3AC-6184C391F352Q34465769-308780F7-74B9-41E7-B63F-054F3627E904Q34478729-F1AB56F5-FA87-4E87-97C0-B42F30ED4411Q34499551-216E13DD-528C-4C78-AD2D-C22395A03951Q34564219-00CF2857-39B1-48E3-A9AC-A01F450BE226Q34584811-7C2670AB-90C3-4A30-B59A-682078A70A57Q34635971-C8F16587-43BE-4901-97E2-D0CC30112CAA
P2860
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Fluorouracil, mitomycin, and r ...... a randomized controlled trial.
@en
type
label
Fluorouracil, mitomycin, and r ...... a randomized controlled trial.
@en
prefLabel
Fluorouracil, mitomycin, and r ...... a randomized controlled trial.
@en
P2093
P356
P1476
Fluorouracil, mitomycin, and r ...... a randomized controlled trial.
@en
P2093
Al B Benson
Charles R Thomas
Christopher Willett
Jaffer A Ajani
John Pedersen
Kathryn A Winter
Leonard L Gunderson
Michael G Haddock
Robert J Mayer
Tyvin A Rich
P304
P356
10.1001/JAMA.299.16.1914
P407
P577
2008-04-01T00:00:00Z